Novel Rapid Test for Detecting Carbapenemase

  26 February 2020

The  fluorescence identification of β-lactamase activity (FIBA) can be performed ≈10 times faster than the most rapid carbapenemase test commercially available while maintaining comparable sensitivity and specificity. Its automated analysis improves turnaround time and reduces operator variability. With a reagent cost/assay of ≈US $1, FIBA is close in price to phenotypic tests but substantially faster and less labor intensive. Furthermore, the FIBA paradigm is extensible; by replacing imipenem with other known subtype-dependent inhibitors of carbapenemase (e.g., clavulanic acid, EDTA), rapid carbapenemase subtyping may also be possible. Our study demonstrates that low-cost, rapid assessment of carbapenemase can be performed in a 1-step format suitable for large-scale epidemiologic studies, thereby providing a new tool for infection outbreak control.

Further reading: CDC
Author(s): Yanfang Feng, Akilan Palanisami, Jerrin Kuriakose, Michael Pigula, Shoaib Ashraf and Tayyaba Hasan
Healthy Animals   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

More information

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed